Cecilia de Barros

Dr. Cecilia de Barros

Universidade de Sorocaba, Sorocaba, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
Juliana Ferreira de SouzaJuliana Ferreira de Souza
Juliana Ferreira de Souza
KPKatiusca da Silva Pontes
Katiusca da Silva Pontes
Thais AlvesThais Alves
Thais Alves
Cecilia de BarrosCecilia de Barros
Cecilia de Barros
VAVenâncio Amaral
Venâncio Amaral
Marco ChaudMarco Chaud
Marco Chaud

10 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Cecilia de BarrosCecilia de Barros
Cecilia de Barros
NANorberto Aranha
Norberto Aranha
Patricia SeverinoPatricia Severino
Patricia Severino
Eliana B. SoutoEliana B. Souto
Eliana B. Souto
AZAleksandra Zielińska
Aleksandra Zielińska
Thais AlvesThais Alves
Thais Alves
The therapeutic use of peptides has increasingly recognized in the development of new therapies. However, the susceptible enzymatic cleavage is a barrier that needs to overcome. Nose-to-brain delivery associated with liposomes can protect peptides against biodegradation and improve the accessibility to brain targets. The aim was to develop a liposomal formulation as ghrelin carrier. The quality by design (QbD) approach was used as a strategy for method development. The initial risk assessments were carried out using a fishbone diagram. A screening design study was performed for the critical material attributes/critical process parameters (CMAs/CPPs) on critical quality attributes (CQAs). Liposomes were obtained by hydrating phospholipid films, followed by extrusion or homogenization, and coated with chitosan. The optimized liposome formulation was produced by high-pressure homogenization coated with chitosan, and the resulted were liposomes size 72.25 ± 1.46 nm, PDI of 0.300 ± 0.027, the zeta potential of 50.3 ± 1.46 mV, and encapsulation efficiency of 53.2%. Moreover, chitosan coating improved performance in ex vivo permeation and mucoadhesion analyzes when compared to the uncoated liposome. In this context, chitosan coating is essential for the performance of the formulations in the ex vivo permeation and mucoadhesion analyzes. The intranasal administration of ghrelin liposomes coated with chitosan offers an innovative opportunity to treat cachexia.

1 October 2019 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
Thais AlvesThais Alves
Thais Alves
Juliana Ferreira de SouzaJuliana Ferreira de Souza
Juliana Ferreira de Souza
VAVenâncio Amaral
Venâncio Amaral
DADanilo Almeida
Danilo Almeida
DGDenise Grotto
Denise Grotto
Marco ChaudMarco Chaud
Marco Chaud

30 July 2018 in Journal of Dispersion Science and Technology
Verified
Journal Article
Closed access
Thais AlvesThais Alves
Thais Alves
Cecilia de BarrosCecilia de Barros
Cecilia de Barros
DBDenicezar Baldo
Denicezar Baldo
VAVenâncio Amaral
Venâncio Amaral
MSMirella Sever
Mirella Sever
Marco ChaudMarco Chaud
Marco Chaud
The aim of the present study was to improve the solubility and dissolution rate of ibuprofen and to evaluate, ex vivo, the intestinal permeation. Solid dispersions (SD) were prepared with Kollicoat IR® by solvent evaporation technique in different drug:carrier ratios. The permeation intestinal of ibuprofen was evaluated by inverted intestinal sac method. The SD was characterized by solubility equilibrium, FT-IR, DSC, PXRD, SEM, and dissolution rate. The solubility, dissolution rate, and permeability were significantly greater for SD 1:2. The PXRD, SEM and DSC indicated a partial change in the crystalline state of ibuprofen. The solubility equilibrium of SD (1:2) was approximately 15 times greater than the solubility of ibuprofen. Dissolution rate enhancement was attributed to the decreased crystallinity of the ibuprofen, and increase of wettability and decrease of particle size. In conclusion, dissolution rate and intestinal permeability of ibuprofen were enhanced by the use of Kollicoat IR® carrier in the SD formulation.

Verified
Journal Article
Open access
PDF file
Cecilia de BarrosCecilia de Barros
Cecilia de Barros
ARAlessandra C. Rios
Alessandra C. Rios
Thais AlvesThais Alves
Thais Alves
FBFernando Batain
Fernando Batain
KCKessi Crescencio
Kessi Crescencio
Marco ChaudMarco Chaud
Marco Chaud
Cachexia, a severe multifactorial condition that is underestimated and unrecognized in patients, is characterized by continuous muscle mass loss that leads to progressive functional impairment, while nutritional support cannot completely reverse this clinical condition. There is a strong need for more effective and targeted therapies for cachexia patients. There is a need for drugs that act on cachexia as a distinct and treatable condition to prevent or reverse excess catabolism and inflammation. Due to ghrelin properties, it has been studied in the cachexia and other treatments in a growing number of works. However, in the body, exogenous ghrelin is subject to very rapid degradation. In this context, the intranasal release of ghrelin-loaded liposomes to cross the blood-brain barrier and the release of the drug into the central nervous system may be a promising alternative to improve its bioavailability. The administration of nose-to-brain liposomes for the management of cachexia was addressed only in a limited number of published works. This review focuses on the discussion of the pathophysiology of cachexia, synthesis and physiological effects of ghrelin and the potential treatment of the diseased using ghrelin-loaded liposomes through the nose-to-brain route.

19 November 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Cecilia de BarrosCecilia de Barros
Cecilia de Barros
Thais AlvesThais Alves
Thais Alves
KCKessi Crescencio
Kessi Crescencio
JAJessica Asami
Jessica Asami
Moema HausenMoema Hausen
Moema Hausen
Marco ChaudMarco Chaud
Marco Chaud
Background/Objectives: Cachexia is a syndrome characterized by the progressive loss of muscle mass, leading to high morbidity and mortality. Ghrelin (Ghrl) exhibits orexigenic, anabolic, and anti-inflammatory properties with therapeutic potential. However, its low bioavailability limits the efficacy of systemic treatments. This study aimed to develop chitosan-coated liposomes containing Ghrl (CH-Lip + Ghrl) for intranasal administration, allowing quantification of Ghrl brain bioavailability using a system optimized for a labile neuropeptide. Methods: The formulation was prepared using thin-film hydration, followed by extrusion and chitosan coating. It was characterized based on morphology, size, zeta potential, stability, encapsulation efficiency, and cell viability. Permeation and mucoadhesion were evaluated ex vivo using porcine nasal mucosa, and cerebral bioavailability was assessed in Wistar rats. Results: CH-Lip + Ghrl had an average of 152.4 ± 0.2 nm (evaluated by DLS), a polydispersity index of 0.159 ± 0.018, a zeta potential of +60.8 ± 6.6 mV, and an encapsulation efficiency of 53.2 ± 0.8%, maintaining stability for 180 days. At 1% (v/v) in culture medium, the formulation retained 73.2 ± 8.4% of the viability in nasal epithelial cells and 81.9 ± 4.8% in neuroblastoma cells. Chitosan coating increased ex vivo mucoadhesion 1.7-fold and permeation 1.3-fold. In vivo, 25 min after intranasal administration, CH-Lip + Ghrl delivered 48.2 ± 8.8% of the dose to the brain, whereas free Ghrl was undetectable. Conclusions: The intranasal administration of CH-Lip + Ghrl enhances cerebral bioavailability of Ghrl. This study integrates a chemically labile neuropeptide with chitosan-coated liposomes for direct brain delivery, representing an innovative platform for future translational studies.